Abatacept, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immunoglobulin (Ig), blocks the CD28:CD80/CD86 co-stimulatory pathway and has recently been introduced as a treatment option for FSGS. The gene discussed is CTLA4; the disease is focal segmental glomerulosclerosis.